Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety

Oligonucleotides

Volumn 15, Issue 2, 2005, Pages 94-104

  Schlingensiepen, Reimar ^a,d   Goldbrunner, Michael ^a   Szyrach, Mara N I ^a   Stauder, Gerhard ^a   Jachimczak, Piotr ^a   Bogdahn, Ulrich ^b   Schulmeyer, Frank ^c   Hau, Peter ^b   Schlingensiepen, Karl Hermann ^a  

^a Antisense Pharma GmbH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Neurosurgery Lohengrin Therme   (Germany)

^d Antisense Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AP 12009; FOMIVIRSEN; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; MALE; MONKEY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; TOXICITY TESTING;

ANIMALS; BRAIN NEOPLASMS; DRUG EVALUATION, PRECLINICAL; GLIOMA; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MACACA FASCICULARIS; MICE; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

MACACA FASCICULARIS; ORYCTOLAGUS CUNICULUS; PRIMATES;

EID: 22044456529     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2005.15.94     Document Type: Article

References (27)

1. BROADDUS, W.C., PRABHU, S.S., GILLIES, G.T., NEAL, J., CONRAD, W.S., CHEN, Z.J., FILLMORE, H., and YOUNG, H.F. (1998). Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J. Neurosurg. 88, 734-742.
2. BROWN, D.A., KANG, S.H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X., and NERENBERG, M.I. 1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
3. CHIASSON, B.J., ARMSTRONG, J.N., HOOPER, M.L., MURPHY, P.R., and ROBERTSON, H.A. (1994). The application of antisense oligonucleotide technology to the brain: Some pitfalls. Cell. Mol. Neurobiol. 14, 507-521.
4. COOK, P.D. (1998). Antisense medicinal chemistry. In: Antisense Research and Application. S.T. Crooke, ed. (Springer, Heidelberg), pp. 51-101.
5. CROOKE, R.M. (1991). In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des. 6, 609-646.
6. FITZPATRICK, D.R., BIELEFELDT-OHMANN, H., HIMBECK, R.P., JARNICKI, A.G., MARZO, A.L., and ROBINSON, B.W. (1994). Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11, 29-44.
7. GALBRAITH, W.M., HOBSON, W.C., GICLAS, P.C., SCHECHTER, P.J., and AGRAWAL, S. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201-206.
8. HENRY, S.P., BOLTE, H., AULETTA, C., and KORNBRUST, D.J. (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120, 145-155.
9. JACHIMCZAK, P., BOGDAHN, U., SCHNEIDER, J., BEHL, C., MEIXENSBERGER, J., APFEL, R., DORRIES, R., SCHLINGENSIEPEN, K.H., and BRYSCH, W. (1993). The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78, 944-951.
10. JACHIMCZAK, P., HESSDORFER, B., FABEL-SCHULTE, K., WISMETH, C., BRYSCH, W., SCHLINGENSIEPEN, K.H., BAUER, A., BLESCH, A., and BOGDAHN, U. (1996). Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int. J. Cancer 65, 332-337.
11. LASKE, D.W., MORRISON, P.P., LIEBERMAN, D.M., CORTHESY, M.E., REYNOLDS, J.C., STEWART-HENNEY, P.A., KOONG, S.S., CUMMINS, A., PAIK, C.H., and OLDFIELD, E.H. (1997a). Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J. Neurosurg. 87, 586-594.
12. LASKE, D.W., MURASZKO, K.M., OLDFIELD, E.H., DEVROOM, H.L., SUNG, C., DEDRICK, R.L., SIMON, T.R., COLANDREA, J., COPELAND, C., KATZ, D., et al. (1997b). Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 41, 1039-1049; discussion 1049-1051.
13. LASKE, D.W., YOULE, R.J., and OLDFIELD, E.H. (1997c). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3, 1362-1368.
14. LECORRE, S.M., BURNET, P.W., MELLER, R., SHARP, T., and HARRISON, P.J. (1997). Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targetting the 5-HT1A receptor. Neurochem. Int. 31, 349-362.
15. LEVIN, A.A., MONTEITH, D.K., LEEDS, J.M., NICKLIN, P.L., GEARY, R.S., BUTLER, M., TEMPLIN, M.V., and HENRY, S.P. (1998). Toxicity of oligonucleotide therapeutic agents. In: Antisense Research and Application. S.T. Crooke, ed. (Springer, Berlin Heidelberg), pp. 169-215.
16. MARZO, A.L., FITZPATRICK, D.R., ROBINSON, B.W., and SCOTT, B. (1997). Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 57, 3200-3207.
17. MAXWELL, M., GALANOPOULOS, T., NEVILLE-GOLDEN, J., and ANTONIADES, H.N. (1992). Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76, 799-804.
18. RAND, R.W., KREITMAN, R.J., PATRONAS, N., VARRICCHIO, F., PASTAN, I., and PURI, R.K. (2000). Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6, 2157-2165.
19. SCHLINGENSIEPEN, G.F., BRYSCH, W., SCHLINGENSIEPEN, K.H., SCHLINGENSIEPEN, R., and BOGDAHN, U. (1994). Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta). Int. Pat. Appl. PCT/EP/94/01362, publ. WO 94/25 588, 10.11.1994.
20. STAUDER, G., HAU, P., BOGDAHN, U., STEINBRECHER, A., BRAWANSKI, A., SCHLAIER, J., WURM, G., PICHLER, J., KUNST, M., and SCHLINGENSIEPEN, K.H. (2003). A TGF-beta2 specific antisense oligonucleotide (AP12009) as continuous intratumoral treatment of recurrent high-grade glioma patients: A clinical phase I/II extension study. Proc. Am. Soc. Clin. Oncol. 22, 109 (Abstract 436).
21. SZKLARCZYK, A., and KACZMAREK, L. (1995). Antisense oligodeoxyribonucleotides: Stability and distribution after intracerebral injection into rat brain. J. Neurosci. Methods 60, 181-187.
22. SZKLARCZYK, A.W., and KACZMAREK, L. (1999). Brain as a unique antisense environment. Antisense Nucleic Acid Drug Dev. 9, 105-116.
23. TAMM, I., DORKEN, B., and HARTMANN, G. (2001). Antisense therapy in oncology: New hope for an old idea? Lancet 358, 489-497.
24. TSUSHIMA, H., KAWATA, S., TAMURA, S., ITO, N., SHIRAI, Y., KISO, S., IMAI, Y., SHIMOMUKAI, H., NOMURA, Y., MATSUDA, Y., et al. (1996). High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 110, 375-382.
25. TZAI, T.S., LIN, C.I., SHIAU, A.L., and WU, C.L. (1998). Antisense oligonucleotides specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res. 18, 1585-1589.
26. WOJCIK, W.J., SWOVELAND, P., ZHANG, X., and VANGURI, P. (1996). Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of lewis rat. J. Pharmacol. Exp. Ther. 278, 404-410.
27. WUNDERLICH, H., STEINER, T., KOSMEHL, H., JUNKER, U., REINHOLD, D., REICHELT, O., ZERMANN, D.H., and SCHUBERT, J. (1998). Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: A tumor-specific marker? Urol. Int. 60, 205-207.